Independent Board Member — Commercial Insurance Broking | Conduct, Client Money & IPO-Path Governance

Reference: GILA/PB/C02/2608
Company stage: Series C
Seat classification: Contractually independent, non-executive private-company board seat; final statutory classification to be confirmed before appointment
Primary board geography: Mumbai and New Delhi with regional branch reviews
Meeting pattern: Seven boards, six Risk/Audit meetings and regulator-facing readiness sessions
Status: Confidential retained-search specification; client identity only after conflict pre-clearance and NDA.

Anonymised company context

A private composite insurance-broking and risk-advisory company serving mid-market corporates, employee-benefit programmes and selected retail affinity partners.

Series C investors have funded acquisitions and technology. Revenue is ₹1,000–1,500 crore with material insurer concentration, acquisition earn-outs and premium/client-money operating processes; an IPO is one strategic option in 24–36 months.

Calibrated market hint: The mid-market corporate focus, acquisition strategy and Mumbai–Delhi footprint describe several scaled private brokers. Candidates must treat any inference as confidential and disclose it only for conflict screening.

Why the seat exists now

The company needs an independent director who understands that growth and placement income must remain subordinate to licence, client interest and disclosure. Acquired broker cultures, contingent remuneration and insurer relationships must be visible before a listing process begins.

At Series C, the company should be building option value: a later IPO, strategic transaction or continued private growth must all remain credible. That requires committee-grade oversight, disclosure-controlled KPIs, a clean group structure, mature risk ownership and decisions that serve the company rather than the timetable of any one shareholder.

Board design, authority and boundaries

Contractual independent director subject to all applicable insurance-broking fit-and-proper and regulatory requirements; Chair of Risk, Conduct & Audit readiness. Final committee architecture will be aligned to licence and future public-company structure.

The appointee is expected to ask for evidence, frame choices, record dissent and hold management accountable. The appointee is not a part-time executive, broker, operating consultant, fundraiser or representative of the investor who proposed the name. Management remains responsible for execution.

Strategic charter — first 18 months

1. Map the licence perimeter, branch/authorised-person controls and regulator commitments across acquired entities
2. Govern client money, premium reconciliation, refunds, unallocated cash and insurer settlements
3. Review placement process, quote evidence, conflicts, contingent commissions and related insurance arrangements
4. Test claims advocacy, complaint, renewal and policy-document outcomes for clients
5. Establish acquisition integration gates for systems, people, licences, earn-outs and customer ownership
6. Oversee cyber, confidential risk data, third-party administrators and business continuity
7. Build disclosure-controlled metrics for premiums placed, revenue, retention, claims and organic growth
8. Design conversion, statutory-board, IICA and LODR workstreams only when the legal timetable makes them applicable

Decisions likely to reach this director

• Whether to place a programme with a higher-paying but weaker-fit insurer
• Whether an acquisition can close before licence and systems integration are ready
• Whether reported organic growth excludes acquisition and pass-through effects correctly

These are not hypothetical interview prompts. They describe the type of decision on which the board expects an independent company-interest view, including the ability to say “not yet,” “only with conditions,” or “stop.”

Candidate market — evidence, not labels

Essential

• Insurance broking, insurer distribution, financial regulation, audit, risk or client-service leader meeting all current suitability requirements
• Client-interest judgement
• Acquisition and branch governance
• Independence from insurers and sponsor funds

Particularly valuable

• Insurance regulator or compliance leadership
• Large client-money reconciliation
• Broker acquisition integration
• Misconduct or commission remediation
• IPO of a regulated intermediary

The search is deliberately open to former operators, founders, functional leaders, investors with genuine board experience, regulators, academics with operating relevance and experienced directors. Prior service on a listed board is useful but not a proxy for judgement.

IICA Databank and legal eligibility position

This search does not impose IICA Independent Directors Databank registration or the proficiency test as a blanket application gate. The disclosed company is presently private, and the seat is designed as a contractually independent non-executive board role. Before appointment, counsel and the Company Secretary will determine whether the company’s actual legal form, public-company status, holding/subsidiary relationships, borrowing or other facts trigger any statutory independent-director requirement. If the seat is later redesignated as a statutory Independent Director role during conversion or IPO preparation, the appointee must complete every then-applicable requirement before that redesignation.

All candidates must still have a valid DIN before appointment, complete required KYC/consent/disclosures, be free of Section 164 disqualification, remain within applicable Section 165 limits, and satisfy the Articles, shareholders’ agreement, investor consent rights and any sector-specific fit-and-proper rules. “Not required to be in the Databank today” does not mean “unregulated” or “low-liability.”

Independence and conflict screens

Relationships with insurers, reinsurers, TPAs, major clients, affinity partners, acquired sellers, sponsor funds or competing brokers; producer commissions; regulator cooling-off or unresolved fit-and-proper matters.

GILA will map pecuniary, advisory, investment, family, customer, supplier, competitor and investor relationships across the look-back period agreed with counsel. A fund nominee is not automatically independent; a well-known listed-company director is not automatically suitable; and a small equity holding is not automatically harmless. Substance and perception will both be assessed.

Downside diligence offered to the candidate

Before consent, the shortlisted candidate will receive under NDA: the cap table and side letters; Articles and shareholders’ agreement; last six board packs and minutes; cash/runway case; material contracts; regulatory, litigation, IP and related-party schedules; insurance policies; founder/KMP employment and equity terms; latest audit or financial review; whistleblower and incident summary; and a written statement of the expected board/committee classification. The candidate may request independent legal advice through an agreed protocol.

First-year evidence of success

The target is a diligence-ready, committee-ready company with auditable operating claims and strategic options that have not been damaged by avoidable governance debt. For this mandate, the board will look for:

• Client money reconciles daily without stale breaks
• Insurer and commission conflicts are governed
• Acquisitions meet licence/control gates
• IPO metrics and related-party disclosures withstand independent review

Commitment, economics and protection

• Expected commitment: 26–34 days annually with regulatory and incident availability.
• Commercial terms: Three-year initial term subject to regulator/company approvals. Fixed fee; no production commission. Equity only if permissible and independence-assessed. Crime, cyber, professional and D&O cover mandatory.
• Minimum protection: a written appointment letter, information and inspection rights, minuting of dissent, a deed of indemnity to the extent legally available, appropriate D&O with advancement and run-off, and access to independent advice.
• No hidden commercial role: no placement fee, sales referral, government liaison, customer introduction or consulting retainer is implied by the board appointment. Any separate engagement would require prior board approval, conflict review and clear disclosure; in many cases it will be prohibited.

Search and appointment process

Conflict pre-clearance → founder and lead-investor conversations held separately → GILA/SYMPHONY™ board-fit assessment → live mandate case → cap-table/SHA and board-pack diligence under NDA → references including one from a difficult company period → joint founder/investor/NRC session → legal, reputation and independence checks → board/shareholder appointment under the constitutional documents.